DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
DEXCOM INC (DXCM) reported that executive officer Sadie Stern, EVP Chief People & Culture Officer, had 1,451 shares of common stock withheld on August 22, 2026 to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units; this was not an open-market sale. After this withholding, Stern directly holds 128,608 shares of Dexcom common stock, including 71,903 unvested restricted stock units that vest on various schedules through March 8, 2029.
DEXCOM INC (DXCM) Executive Chair Kevin R. Sayer reported open-market sales of a total of 26,756 shares of common stock on August 20, 2026, in three transactions at weighted average prices of about $89.71, $90.78, and $91.41. These sales were made under a Rule 10b5-1 trading plan adopted on February 18, 2026. Sayer continues to hold equity awards, including 106,972 unvested restricted stock units with grants from 2024–2026 that vest through dates in 2027 and 2028.
DEXCOM, INC. (DXCM) received a Rule 144 notice from Kevin R. Sayer covering a proposed sale of 26,756 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $2,408,240.67 and an anticipated sale date of 08/20/2026. The shares derive from restricted stock acquired from the issuer on 01/28/2025. The notice also lists prior sales over the past three months.
DEXCOM INC executive Michael Jon Brown, EVP Chief Legal Compliance Officer, reported selling 1,700 shares of common stock on August 14, 2026 at $91.93 per share in an open-market transaction under a pre-arranged Rule 10b5-1 Plan. Following this sale, he directly holds 102,953 shares, including 74,753 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029.
Michael Brown filed a Form 144 to potentially sell 1,700 shares of DXCM common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an estimated aggregate market value of $156,281.00 as of 08/14/2026. The filing also lists prior sales of 1,700 shares each on 05/15/2026 for $101,847.00, on 06/15/2026 for $128,435.00, and on 07/15/2026 for $126,514.00.
DEXCOM INC director Nicholas Augustinos reported a bona fide gift of 1,075 shares of Dexcom common stock on 2026-08-12. The donated shares were held indirectly through the Kirschner/Augustinos Revocable Trust and were contributed to a charitable donor advised fund, leaving 37,382 shares held by the trust. Separately, Augustinos holds 5,575 unvested restricted stock units granted on May 28, 2026, which will vest on the earlier of the one-year anniversary of that grant or DexCom, Inc.'s 2027 Annual Meeting of Stockholders.
DexCom Inc. director Bridgette P. Heller reported an open-market sale of 1,012 shares of Common Stock on August 12, 2026 at $88.29 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on August 14, 2025. After this transaction, she directly holds 29,570 shares, including 5,575 unvested restricted stock units that were granted on May 28, 2026 and will vest on the earlier of the one-year anniversary of the grant date or DexCom’s 2027 Annual Meeting of Stockholders.
DexCom, Inc. insider Bridgette P. Heller filed a notice of proposed sale of 1,012 shares of common stock of DXCM, to be sold through Fidelity Brokerage Services LLC on or after August 12, 2026 on NASDAQ. The shares were acquired via restricted stock vesting from the issuer as compensation on September 29, 2021. Heller also reported having sold 1,012 common shares during the past three months on May 12, 2026 for $60,730.12.
A family trust associated with DexCom Inc. director Mark G. Foletta sold 4,000 shares of common stock in two indirect open-market transactions: 2,000 shares at $80.00 on July 31, 2026 and 2,000 shares at $85.32 on August 3, 2026, pursuant to a pre‑arranged 10b5‑1 Plan adopted by the Foletta Family Trust on March 13, 2026.
Foletta also directly holds 6,331 unvested restricted stock units granted on May 28, 2026, scheduled to vest on the earlier of the one‑year grant anniversary or DexCom’s 2027 annual meeting of stockholders.
DexCom, Inc. (DXCM) has a planned sale by The Foletta Family Trust under a Form 144 notice. The trust intends to sell 2,000 shares of common stock through UBS Financial Services on NASDAQ, with an indicated aggregate value of $170,640.00. The shares derive from 2,000 vested RSUs granted by the issuer on 05/31/2019.
The filing also lists recent sales by the trust: 4,000 shares of common stock sold on 06/15/2026 for $296,539.60, and 2,000 shares sold on 07/31/2026 for $160,000.00. These transactions provide context for the trust’s ongoing disposition of DXCM shares.